What are the reimbursement conditions for Jisandai (Bingtonsha) medical insurance?

Epclusa (Epclusa) is a drug used to treat chronic hepatitis C (HCV). It is a new direct-acting antiviral drug (DAA) developed by the American pharmaceutical company Gilead Sciences. It was approved for marketing by the U.S. Food and Drug Administration (FDA) in 2016. It is a revolutionary treatment option.

Jisandai (Bingtonsha) has been officially launched in China and has also been included in the medical insurance system. Therefore, patients can easily purchase it in China. Its selling price is approximately in the range of two to three thousand yuan, but the specific price and relevant policies for medical insurance reimbursement vary by region. It is recommended that you consult the nearest hospital pharmacy to obtain the most accurate information.

In addition, if you are looking for a more economical option, foreign Generic drugs of Jisandai (Bintongsha) will be an option to consider, especially the versions produced in Bangladesh and India. The price of these generic drugs usually ranges from a few hundred to more than a thousand yuan, and their pharmaceutical ingredients are basically the same as domestic original drugs. If you consider this option, make sure to purchase from a reliable source and seek the advice of your doctor.

Hepatitis C is a chronic viral infection caused by the hepatitis C virus (HCV) that, if left untreated, can lead to severe liver damage, including cirrhosis and liver cancer. In the past, the treatment of hepatitis C mainly relied on drugs such as interferon and ribavirin, but these treatment options have limited efficacy and are often accompanied by serious side effects.

Gisanda (Bingtonsa) is a combination drug that contains two different drug ingredients: Sofosbuvir (Sofosbuvir) and vimibuvir (Velpatasvir). Sofosbuvir is a nucleoside analog that inhibits HCV RNA polymerase, thereby preventing viral replication. Vimibuvir is an NS5A inhibitor that can prevent HCV replication and assembly in host cells, thereby reducing the number of viruses.

Ji Sandai (Bingtongsha)The advantages are its high efficacy, short treatment cycle, usually 12 weeks, and relatively few side effects. Clinical studies have shown that Bentongsa can achieve durable virological cure in the majority of patients, even in patients who have previously failed other treatment options. This makes Jisandai (Bingtonsa) one of the first-choice drugs for the treatment of hepatitis C.